All In Biotech

Drug Trial Radar · NCT05667194

Phase 1 Trial of KH617

A Phase 1 Study to Assess the Safety ,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of KH617 After SAD and MAD Administration for Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 26, 2022

Primary completion

Sep 2030

Study completion Aug 2031

Sponsor

Sponsor type
Industry
First posted
Dec 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.

Conditions

  • Advanced Solid Tumors

Interventions

  • KH617Drug

    KH617 is s freeze-dried powder injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: 90 weeks
  2. DLTTime frame: 90 weeks
  3. RP2DTime frame: 154 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Titan Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.